Multiomics Market Size, Share and Trends 2026 to 2035

What is the Multiomics Market Size?

The global multiomics market size is calculated at USD 3.24 billion in 2025 and is predicted to increase from USD 3.70 billion in 2026 to approximately USD 13.20 billion by 2035, expanding at a CAGR of 15.18% from 2026 to 2035. The multiomics market is driven by the growing adoption of precision medicine and advanced omics technologies.

Multiomics Market Key Takeaways

• In terms of revenue, the global multiomics market was valued at USD 3.24 billion in 2025.
• It is projected to reach USD 13.20 billion by 2035.
• The market is expected to grow at a CAGR of 15.18% from 2026 to 2035
• North America accounted for the largest revenue share of 45.73% in 2025.
• Asia Pacific is expected to grow at a significant CAGR of 18.35% from 2026 to 2035.
• By offering/component, the products segment dominated the market with the largest share of 79% in 2025.
• By offering/component, the services segment is expected to grow at the fastest CAGR of 15.80% between 2026 and 2035.
• By platform, the genomics segment held the largest market share of 39.47% in 2025.
• By platform, the proteomics segment is expected to expand at the fastest CAGR of 15.86% in the upcoming period.
• By application, the oncology segment dominated the market in 2025, accounting for the largest share of 39%.
• By application, the neurology segment is expected to expand at the fastest CAGR of 15.92% over the forecast period.
• By end user, the academic & research institutes segment led the market, holding a major share of 47% in 2025.
• By end user, the pharmaceutical & biotechnology companies segment is expected to grow at the fastest CAGR of 17.15% in the coming years.
• By type, the bulk multiomics segment held the dominant market share of 62% in 2025.
• By type, the single-cell multiomics segment is expected to grow at the fastest CAGR of 18.15% over the projection period.
• By technology, the next-generation sequencing (NGS) segment dominated the market with largest share of 49% in 2025 and is expected to sustain its dominance throughout the
• forecast period.

Market Overview

The multiomics market encompasses the integrated analysis of data across multiple omics domains, including genomics, proteomics, transcriptomics, metabolomics, and epigenomics, to gain a comprehensive, system-level understanding of biological processes. This approach is driving significant growth due to its potential to revolutionize personalized medicine, biomarker discovery, drug development, and clinical diagnostics by combining diverse molecular data types to uncover disease mechanisms, patient responses, and therapeutic targets. The rising prevalence of various life-threatening diseases, high demand for precision medicine, and advances in next-generation sequencing technologies are boosting the growth of this market.

How is AI Transforming the Multiomics Market?

Artificial intelligence is transforming the multiomics market by enabling faster and more efficient analysis of large datasets from various omics fields, leading to breakthroughs in understanding diseases, drug discovery, and personalized medicine. AI algorithms can integrate and analyze data from genomics, proteomics, metabolomics, and other sources to identify disease subtypes, drug targets, and biomarkers. AI also accelerates drug discovery by identifying potential drug targets, predicting efficacy, and optimizing drug design, contributing to improved diagnoses and prognoses. It can develop predictive models to identify individuals at risk for certain diseases or predict their treatment responses.

• In October 2024, at the ESGCT Congress, Whitelab Genomics shared key insights on how AI can transform genomic medicine. Their platform uses extensive datasets to create in-silico simulations that streamline the design and optimization of AAV vectors, drastically reducing development timelines while improving targeting specificity, aiming to unlock the full potential of genomic medicine.

What Are the Key Trends in the Multiomics Market?

• Increasing Prevalence of Chronic Diseases: The rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular diseases, is driving the demand for multiomics approaches to understand disease mechanisms and identify new therapeutic targets, leading to more effective diagnostic and therapeutic strategies.
• Growing Demand for Single-Cell Multiomics: The emergence of single-cell multiomics is enabling researchers to study cellular heterogeneity and dynamics at an unprecedented level, gaining traction, and leading to discoveries in disease and treatment response, thereby further expanding the market.
• Increased Research and Development Investments: Investments in multiomics research and development by pharmaceutical and biotechnology companies are accelerating the development and adoption of multiomics technologies for the translation of multiomics research into clinical applications.
• Advancements in Technologies: Advances in high-throughput technologies, such as next-generation sequencing (NGS) and mass spectrometry, combined with advanced data analysis tools and bioinformatics, are enabling more efficient and comprehensive multiomics analysis, significantly improving the ability to generate vast amounts of omics data and driving the growth of multiomics.

Market Scope

Market Dynamics

Drivers

Increasing Drug Discovery and Development

The major driver in the multiomics market is the increasing drug discovery and development. Multiomics offers a more comprehensive understanding of disease mechanisms, enabling more targeted therapeutic approaches. Multiomics combines data from various omics fields to offer a holistic view of disease at the molecular level, which helps identify new drug targets and pathways involved in disease development. Therefore, by analyzing an individual's multi-omics profile, researchers can identify biomarkers that predict drug response, leading to the development of personalized therapies tailored to specific patient characteristics. It can also uncover new indications for existing drugs and speed up their repurposing for new therapeutic areas.

• In January 2025, Enhanc3D Genomics announced the launch of a suite of integrated multi-omics solutions designed to accelerate and improve the precision of drug discovery. Built on the Company's proprietary 3D genomics platform and integrated with extensive multi-omics analysis, the new 3D Multi-omics offerings provide partners with a comprehensive end-to-end solution to support and enhance decision-making throughout every stage of the drug discovery and development process.

Restraint

High Cost and Complexity of Data Analysis and Integration

The primary restraint in the multiomics market is the high cost and complexity of data analysis and integration. This includes the need for specialized equipment and advanced bioinformatics software across genomics, proteomics, transcriptomics, and metabolomics, as well as highly skilled personnel with expertise in bioinformatics, data analysis, and interpretation. This makes adoption expensive for many institutions and companies. Different omics datasets have varying formats and structures, making integration and analysis challenging. Developing and implementing robust bioinformatics pipelines for multiomics analysis is complex and time-consuming.

Opportunity

Rising Demand for Personalized Medicine and Precision Diagnostics

The key future opportunity in the multiomics market lies in the rising demand for personalized medicine and precision diagnostics. Multiomics helps customize medical treatments based on individual patient profiles by integrating data from genomics, transcriptomics, proteomics, and metabolomics to gain a deeper understanding of disease mechanisms. This leads to more effective, personalized healthcare. Multiomics can help identify new drug targets and predict treatment responses, facilitating the development of more targeted therapies. Researchers can also discover novel biomarkers for early disease detection and prognosis by analyzing multiple omics layers.

Segment Analysis

Products Insights

The Instruments Segment Held the Largest Share of the Multiomics Market in 2025

The instruments segment held a dominant position in the market in 2025 due to advanced sequencing devices, mass spectrometers, and analytical systems. The instruments can provide multiomics analysis with higher throughput and precision. Research labs and drug companies are still making investments in new high-tech lab equipment.

The services segment is expected to witness strong growth during the forecast period as more multiomics research and data analysis are becoming outsourced to organisations. Providers support the operations and can support sequencing, bioinformatics, and analysis. Collaborations with contract research organizations (CROs) in the field of R&D are helping to drive demand.

The consumables segment is projected to grow at a notable pace as sequencing is likely to be repeated, and sample preparation and molecular analysis will be required again and again. Multiomics studies are routine and require reagents, assay kits, and laboratory chemicals. Research & clinical testing have led to the use of products.

The software segment is expected to witness steady growth during the forecast period as the need for bioinformatics and data analysis using AI grows. Efficient integration and interpretation of complex multiomics data are made possible by advanced software platforms. Collaboration and research productivity are enhanced with the use of cloud-based analytical tools.

Multiomics Market Size, By Offering, 2023 to 2025 (USD Million)

Platform Insights

The Genomics Segment Dominated the Multiomics Market in 2025

The genomics segment dominated the market in 2025 because of its use in disease diagnosis as well as in genetic testing and research for precision medicine. Next-generation sequencing technologies have greatly improved the capacity to analyse genomes. Genomics programs continue to be very well funded in both the government and research organisation sectors.

The proteomics segment is expected to grow rapidly during the forecast period due to the increasing need for identification and development of protein biomarkers. New mass spectrometry technologies allow proteins to be characterized in detail. Proteomics, the analysis of proteins, is helping pharmaceutical companies to speed up the process of drug discovery and personalized medicine.

The transcriptomics segment is projected to grow at a notable pace due to its ability to analyse gene expression and cell response. Transcriptomic technologies are becoming increasingly popular to gain a deeper insight into disease processes and disease response to treatment. RNA sequencing has advanced significantly in technology to provide more accurate and speedy analysis.

The metabolomics segment is expected to witness steady growth during the forecast period due to the growth of interest in metabolomics profiling and the identification of biomarkers. Incorporating advanced analytical technologies, a comprehensive analysis of metabolites is possible that are associated with the progression of a disease. The use in clinical diagnostics, nutrition, and pharmaceuticals grows.

Multiomics Market Size, By Platform, 2023 to 2025 (USD Million)

Application Insights

The Oncology Segment Dominated the Multiomics Market in 2025

The oncology segment led the market in 2025, as the development of multiomics technologies for cancer diagnosis, discovery of cancer biomarkers, and targeted therapy for cancer has increased. Researchers are compiling all the genomic, proteomic, and metabolomic data to better inform treatment decisions. The amount of money invested in cancer research has increased, and cancer is becoming a problem in the world.

The neurology segment is expected to grow fastest during the forecast period as scientists increasingly turn to multiomics to probe into complex neurological disorders. These technologies include increased understanding of disease mechanisms and discovery of biomarkers. As the number of research works that focus on Alzheimer's, Parkinson's and other neurodegenerative diseases is increasing, this is fueling the demand.

The immunology segment is projected to grow at a healthy pace with the ability to analyze the entire picture of immune responses and disease progression by multiomics technologies. The use of integrated omics information in the development of personalized immunotherapies and vaccines. Investigations are being made in an attempt to discover treatments for these autoimmune diseases, as their prevalence has grown.

The cell biology segment is expected to experience considerable growth during the forecast period, driven by the growing interest in single-cell and spatial multiomics technologies. They are used to convey information on the role of the cells and on biological pathways. The research and investment of academic institutions and biotechnology companies are advancing in the field of advanced cell analysis.

Multiomics Market Share, By Application, 2025 (%)

End-user Insights

The Academic & Research Institutes Segment Dominated the Multiomics Market in 2025

The academic & research institutes segment held a major share of the market in 2025, as substantial investment is being made in life Sciences & Biomedical research. In the field of institutions of higher learning and research institutions, advanced multiomics technologies are crucial. Government funding of research in genomics and systems biology is still high.

The pharmaceutical & biotechnology companies segment is expected to witness rapid growth with investments towards drug discovery and precision medicine. Marker identification and therapeutic target validation are being expedited by multiomics technologies. AI and bioinformatics have come to the rescue to improve the efficiency of research.

Multiomics Market Size, By End User, 2023 to 2025 (USD Million)

Type Insights

The Bulk Multiomics Segment Led the Multiomics Market in 2025

The bulk multiomics segment dominated the market in 2025, as it is used in large-scale studies or population biological analysis. Provides low-cost analysis of tissue and cell samples at multiple levels of omics analysis. The bulk workflows are employed in research institutes and research projects for finding research markers.

The single-cell multiomics segment is predicted to expand at a rapid CAGR, as the need for this analysis is likely to grow as the resolution of analysis of a single cell increases. The study of cellular heterogeneity and disease progression is explored using single-cell technologies. New sequencing and bioinformatics tools are increasing analytical capabilities.

Multiomics Market Size, By Type, 2023 to 2025 (USD Million)

Technology Insights

The Next-Generation Sequencing (NGS) Segment Was Dominant in the Multiomics Market in 2025

The next-generation sequencing (NGS) segment registered dominance in the market in 2025 due to its higher throughput, accuracy, and cost-effective genomic analysis. It is a technology widely used in genomics studies, transcriptomics, and integrated multiomics studies. Sequencing is getting quicker and faster, and the data is even getting better and better.

The mass spectrometry (MS) segment is estimated to grow rapidly with the development of advancements in proteomics and metabolomics analysis. A modern mass spectrometer has very accurate molecular characterization and identification of biomarkers. These kinds of technologies have been becoming increasingly common in the pharmaceutical and clinical trial sectors.

The PCR & microarrays segment is expected to grow steadily, as a well-established application field in molecular diagnostics and gene expression studies. These are still the technologies being utilized in clinical and normal research. They are cheap and easily accessible and will continue to be used.

Multiomics Market Share, By Technology, 2025 (%)

Region Insight

How did North America Dominate the Multiomics Market in 2025?

North America dominated the global market in 2025 due to its high levels of advanced healthcare facilities and the presence of key biotechnology and life sciences companies. There is extensive investment in the region in both genomics and precision medicine and biomedical research. Government grants and research projects help speed the uptake of multiomics technologies. The widespread adoption of next-generation sequencing techniques and bioinformatics enabled by AI further drives market growth.

U.S. Multiomics Market Size and Growth 2026 to 2035

The U.S. multiomics market size was exhibited at USD 1.19 billion in 2025 and is projected to be worth around USD 4.01 billion by 2035, growing at a CAGR of 13.02% from 2026 to 2035.

U.S. Market Trends

U.S. market is anticipated to grow significantly, driven by the rising investments in precision medicine, genomics research, and drug discovery. The multiomics platforms are becoming more common in many academic institutions, pharmaceutical companies, and research institutes. Rising use of bioinformatics and cutting-edge sequencing techniques with artificial intelligence is making research more efficient. Innovation in biomedical research and personalized healthcare is being supported by the government.

Why is the Asia Pacific Witnessing Rapid Growth in the Multiomics Market?

Asia Pacific is expected to grow at the fastest rate in the market as a result of quick biotechnology research development and the establishment of healthcare infrastructure in the region. Precision medicine, genomics, and life sciences innovation are a priority in investment for the governments in the region. As institutions are increasingly partnering with biotechnology firms, technology is being rapidly adopted. Advanced molecular research tools are in demand due to increasing chronic diseases.

China Market Trends

China's market is anticipated to grow significantly, with significant funding of research and innovation in the genomics segment and precision medicine initiatives. The policies of innovation are actually playing their part in the country's fast-growing biotechnology and pharma industry. The use of AI, next-generation sequencing, and advanced bioinformatics is supporting the research. Integrated Multiomics platforms are in demand due to population genomics projects.

Ongoing Advancements in Multiomics Drive Europe

Europe is expected to witness significant multiomics market growth throughout the forecast period as the countries are investing more in R&D for the life sciences industry and personalized medicine. Innovation is sped up by good cooperation between research institutes, healthcare institutions, and biotechnology enterprises. Funding and supportive regulations from the government are encouraging the uptake of technology by encouraging genomics programmes. Multiomics is increasing due to the rising need to discover biomarkers and do translational research.

Germany Market Trends

Germany market is anticipated to grow significantly, owing to the robust biotechnology industry and excellent research environment in the country. Much effort continues to be invested in precision medicine, genomics, and molecular diagnostics research within the country. The rise in the use of sophisticated multiomics technologies in pharmaceutical research and drug development, as well as in academic research on diseases, highlights the significance of these technologies. With the government's support, a research ecosystem is being formed.

Surging Key Trends in Multiomics Propel Latin America

Latin America is expected to witness lucrative growth in the multiomics market due to the high investment in healthcare research and biotechnology infrastructure. Genomics and precision medicine initiatives have been actively encouraged in many countries worldwide with the aim of early disease detection and treatment. Also, academic ties and international scientific collaborations expedite technology adoption. Multiomics platforms are growing in use as a result of a growing emphasis on personalised medicine.

Brazil Market Trends

Brazil market is anticipated to grow significantly, driven by increasing investments in life sciences research and the modernization of the Healthcare sector. Genomics and proteomics technologies are being increasingly used by research institutions to research diseases. Government support to encourage the development of biotechnology innovations is leading to the use of advanced analytical platforms. The expansion of pharmaceutical research and clinical trials is opening up new market opportunities.

Government Encouragement is fueling the Middle East and Africa

The Middle East and Africa region is predicted to show a notable expansion in the multiomics market as healthcare infrastructure and biomedical research in the region are being heavily invested in. There have been calls by Governments for genomics programs and precision medicine initiatives to improve healthcare systems. Increased use of advanced molecular diagnostics is driving the growth of the application of multiomics technologies. The market is expected to grow further, as chronic diseases are becoming more prevalent.

Saudi Arabia Market Trends

Saudi Arabia market is anticipated to grow significantly. The government is investing in and promoting genomics research and precision medicine initiatives. Modern sequencing and bioinformatics technologies are being implemented in healthcare institutions for better management of disease. The strategic alliance with partners from the life sciences sector around the world is helping speed up research.

Value Chain Analysis

• Raw Material and Data Sourcing
  The foundation of multiomics begins with the collection of biological samples such as tissues, blood and cells. Quality is of great priority in this stage as it helps to determine data reliability. In the recent years, the demand for high throughput, high volume reagent kits and consumables has surged, making scalability and consistency a priority for suppliers. This growth is driven by large pharmas and research.
  Key Players: Agilent, Thermo Fisher, Bio Rad
• Manufacturing Process
  This stage involves building the core of any multiomics platform. Manufacturers all over the world are expanding the production of high throughput instruments and consumables in order to meet the growing demand. Because multiomics data generation creates massive amounts of data sets, companies are also seen investing in computational infrastructure like servers, cloud based platforms and advanced data storage softwares.
  Key Players: Illumina, Perkin Elmer, Bruker Corporation
• Product Innovation and Designing
  This stage focuses on improving instruments as well as refining workflows by combing various omics layers in order to deliver holistic biological insights, thus enabling precision medicine, biomarker discovery and systems biology research. A major trend in this stage is the rise of single cell multiomics, which allows researchers to analyze cellular nuances and disease mechanisms on a much deeper level.
  Key Players: Thermo Fisher, BGP Genomics, QIAGEN

Competitive Landscape

The multiomics market comprises life sciences companies, biotechnology firms, sequencing technology, and analytical instrument manufacturers. Thermo Fisher Scientific, Illumina, Inc., Agilent Technologies, QIAGEN, and Bruker Corporation are the key players. The development of next-generation sequencing, mass spectrometry, AI-driven bioinformatics, product innovation, and strategic partnerships are the areas of their focus for enhancing their competitive edge.

The players are expanding their footprint with partnerships with research institutes, healthcare organizations, pharmaceutical companies, and biotechnology companies. To strengthen their product lines and research facilities, companies are increasingly acquiring companies, building advanced omics platforms and as an addition to the products developing solutions for precision medicine. As the demand for precision medicine, new biomarkers, and integrated multiomics technologies develops, continuous innovation and more competition will be seen in the global market.

Multiomics Market Companies

• Thermo Fisher Scientific
• Illumina, Inc.
• Agilent Technologies
• QIAGEN
• Bruker Corporation
• BGI Genomics
• PerkinElmer (now part of Revvity)
• Waters Corporation
• Bio-Rad Laboratories
• 10x Genomics

Latest Announcement by Industry Leader

• In January 2025, Illumina, Inc. collaborated with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research, genomics AI development, and drug discovery. Rory Kelleher, senior director, global head of business development, healthcare and life sciences at NVIDIA, said, "Combining Illumina's world-leading sequencing and analytics platforms with NVIDIA's accelerated computing and AI, we will drive the next generation of genomics interpretation and democratize genomics for drug discovery through AI-powered insights."

Segments Covered in the Report

By Products

• Instruments
• Consumables
• Software
• Services

By Platform

• Genomics
• Transcriptomics
• Proteomics
• Metabolomics

By Application

• Oncology
• Neurology
• Immunology
• Cell Biology

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

By Type

• Single-cell Multiomics
• Bulk Multiomics

By Technology

• Next-Generation Sequencing (NGS)
• Mass Spectrometry (MS)
• PCR & Microarrays

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa